Literature DB >> 27665385

Development and Initial Validation of a Questionnaire to Measure Health-Related Quality of Life of Adults with Common Variable Immune Deficiency: The CVID_QoL Questionnaire.

Isabella Quinti1, Federica Pulvirenti2, Patrizia Giannantoni3, Joud Hajjar4, Debra L Canter4, Cinzia Milito2, Damiano Abeni3, Jordan S Orange4, Stefano Tabolli5.   

Abstract

BACKGROUND: Generic health status quality of life (QoL) instruments have been used in patients with common variable immune deficiency (CVID). However, by their nature, these tools may over- or underestimate the impact of diseases on an individual's QoL.
OBJECTIVE: The objective of this study was to develop and validate a questionnaire to measure specific-health-related QoL for adults with CVID (CVID_QoL).
METHODS: The 32-item content of the CVID_QoL questionnaire was developed using focus groups and individual patient interviews. Validation studies included 118 adults with CVID who completed Short Form-36, Saint George Respiratory Questionnaire, General Health Questionnaire-12, and EuroQol-5D questionnaire in a single session. Principal component and factor analysis solutions identified 3 scores to be similar in number and content for each solution. Validation of 3 factor scores was performed by construct validity. Reproducibility, reliability, convergent validity, and discriminant validity were evaluated. Matrices consisting of correlations between the 32 items in the CVID_QOL were calculated.
RESULTS: Factor analysis identified 3 dimensions: emotional functioning (EF), relational functioning (RF), and gastrointestinal and skin symptoms (GSS). The instrument had good internal consistency (Cronbach's alpha, min. 0.74 for GSS, max. 0.84 for RF, n = 118) and high reproducibility (intraclass correlation coefficient, min. 0.79 for RF, max 0.90 for EF, n = 27). EF and RF scores showed good convergent validity correlating with conceptually similar dimensions of other study scales. Acute and relapsing infections had a significant impact on EF and RF.
CONCLUSIONS: This study provides evidence of the reliability and construct validity of the CVID_QoL to identify QoL issues in patients with CVID that may not be addressed by generic instruments.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Burden of disease; CVID_QoL; Common variable immune deficiency; Disease-specific questionnaire; Quality of life; Questionnaire validation

Mesh:

Year:  2016        PMID: 27665385     DOI: 10.1016/j.jaip.2016.07.012

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  13 in total

Review 1.  The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative.

Authors:  Albert Farrugia; Giuliano Grazzini; Isabella Quinti; Fabio Candura; Samantha Profili; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

2.  Primary Immunodeficiency: New Insights and Practical Clinical Approaches.

Authors:  Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

3.  30-Year Review of Pediatric- and Adult-Onset CVID: Clinical Correlates and Prognostic Indicators.

Authors:  Carolyn Baloh; Anupama Reddy; Michele Henson; Katherine Prince; Rebecca Buckley; Patricia Lugar
Journal:  J Clin Immunol       Date:  2019-08-03       Impact factor: 8.317

4.  Provider Perceptions of Quality of Life, Neurocognition, Physical Well-being, and Psychosocial Health in Patients with Primary Immunodeficiency/Immune Dysregulation Conditions.

Authors:  Thomas F Michniacki; Kelly J Walkovich; Lauren E Merz; Julie Sturza; Roshini S Abraham
Journal:  J Clin Immunol       Date:  2019-10-26       Impact factor: 8.317

5.  Health-Related Quality of Life and Emotional Difficulties in Chronic Granulomatous Disease: Data on Adult and Pediatric Patients from Italian Network for Primary Immunodeficiency (IPINet).

Authors:  Federica Pulvirenti; Maria Sangerardi; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Antonino Trizzino; Alessandro Aiuti; Maddalena Migliavacca; Franco Locatelli; Alice Bertaina; Samuele Naviglio; Maria Carrabba; Marco De Carli; Maria Grazia Foschino Barbaro; Marco Gattorno; Isabella Quinti; Baldassarre Martire
Journal:  J Clin Immunol       Date:  2019-12-20       Impact factor: 8.317

6.  Health-Related Quality of Life and Patients' Empowerment in the Health Care of Primary Immune Deficiencies.

Authors:  Isabella Quinti; Federica Pulvirenti
Journal:  J Clin Immunol       Date:  2017-08-17       Impact factor: 8.317

7.  Assessing Disease Severity in Common Variable Immunodeficiency Disorders (CVID) and CVID-Like Disorders.

Authors:  Rohan Ameratunga
Journal:  Front Immunol       Date:  2018-09-28       Impact factor: 7.561

8.  The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data.

Authors:  Irina Odnoletkova; Gerhard Kindle; Isabella Quinti; Bodo Grimbacher; Viviane Knerr; Benjamin Gathmann; Stephan Ehl; Nizar Mahlaoui; Philippe Van Wilder; Kris Bogaerts; Esther de Vries
Journal:  Orphanet J Rare Dis       Date:  2018-11-12       Impact factor: 4.123

9.  What Is the Burden of Immunoglobulin Replacement Therapy in Adult Patients With Primary Immunodeficiencies? A Systematic Review.

Authors:  Georgina L Jones; Katharina S Vogt; Duncan Chambers; Mark Clowes; Anna Shrimpton
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

10.  Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study.

Authors:  Federica Pulvirenti; Francesco Cinetto; Antonio Pecoraro; Maria Carrabba; Ludovica Crescenzi; Raffaella Neri; Livia Bonanni; Giovanna Fabio; Carlo Agostini; Giuseppe Spadaro; Stefano Tabolli; Albert Farrugia; Isabella Quinti; Cinzia Milito
Journal:  J Clin Immunol       Date:  2019-01-15       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.